Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119558 · ClinicalTrials.gov registry record · Early Phase 1
PET/MRI Evaluation of Cardiac Amyloid
A Early Phase 1 study of Cardiac Amyloidosis, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03119558: Completed Early Phase 1 study of Cardiac Amyloidosis, sponsored by Stanford University.
NCT03119558 is a Early Phase 1 study of Cardiac Amyloidosis that has completed, run by Stanford University. The registered enrollment target is 9 participants, below the 954-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03119558, a Early Phase 1 study of Cardiac Amyloidosis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.
Primary Outcome
Diffuse (widespread), focal (point) and focal-on-diffuse (combination of the two) patterns of 18F-Florbetaben uptake will be considered positive findings indicating cardiac amyloidosis
Conditions Studied
Interventions
- DRUG 18F-Florbetaben (Neuraceq®) PET/MRI
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-05-26 |
| Est. Completion | 2018-08-28 |
| Phase | Early Phase 1 |
What the finished NCT03119558 record still lists
NCT03119558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 954-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 18F-Florbetaben (Neuraceq®) PET/MRI is the first listed.
NCT03119558 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03119558 about?
NCT03119558 is a clinical study titled "PET/MRI Evaluation of Cardiac Amyloid". Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid c...
What is the current status of trial NCT03119558?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2016-05-26. Estimated completion is 2018-08-28.
What conditions does trial NCT03119558 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis.
What interventions are being tested in trial NCT03119558?
The interventions under investigation include: 18F-Florbetaben (Neuraceq®) PET/MRI (DRUG).
Who is sponsoring clinical trial NCT03119558?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03119558 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03119558's enrollment target sits among peer trials
9 9th of 8 the lowest of 8 other Cardiac Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
RECRUITING · NA
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
US Benchmarking Clinical Study
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI